ISRG vs SNY
Intuitive Surgical vs Sanofi — AI-powered side-by-side comparison
ISRG
Intuitive Surgical
60
Buy
VS
| Metric | ISRG | SNY |
|---|
| AI Score |
60
|
66
|
| Price |
$371.73
|
$46.00
|
| P/E Ratio |
42.21×
|
24.00×
|
| ROE |
16.0%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.7%
|
72.8%
|
| Debt / Equity |
0.00×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.3%
|
| RSI (14) |
40.0
|
67.8
|
| Beta |
1.46
|
0.278
|
| Expected Upside |
+18.5%
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for ISRG versus SNY.
SNY leads by 6 points.
SNY scores 66/100 (Buy) versus ISRG at 60/100 (Buy).
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth